Issue 3 · July 10, 2026 · 5 min read
Older Lifters Have the Muscle of Younger Adults
Trained older adults have muscle gene activity that looks years younger
Good news if you lift: in older adults who kept training, about half the molecular signs of muscle aging simply weren't there. Also this week, a way to soften the aging of ovaries, an AI-designed drug reaching its final trial, a hard look at fish oil, and a billion-dollar peptide gold rush. Here's what's worth knowing:
Aging cells go quiet: Older cells turn down their own volume, making fewer of the messages that keep them running, and in worms, nudging that dial shifted lifespan. Early, not yet peer-reviewed.
Aging clocks, a humility check: A Nature Medicine review from Eric Topol and Tony Wyss-Coray calls biological-age tests promising research tools, but not yet validated enough to steer your care.
Fish-oil reality check: A New York Times evidence review found omega-3 pills reach the brain but haven't improved memory or dementia risk in trials; for the brain, food may beat the pill.
Vet your online script: A JAMA secret-shopper test of 49 online GLP-1 sellers found 92% wrote a prescription with barely any clinician contact, a reason to insist on a real exam before you buy.
Cheaper full-body testing: Fountain Life opened a $595-a-year tier with a whole-body scan and blood workup, pulling the kind of testing that once cost many times more toward the mainstream.
Peptides, graded: Amid the peptide gold rush, the nonprofit Forever Healthy now posts free, plain-English verdicts on the peptides people are buying, so you can check the evidence before trying one.
Lasers vs skin aging: A laser nudged skin's aging markers younger in a trial of Candela's Nordlys device, an early industry signal. Just 22 people, and the maker funded it.
Living longer, by the numbers: New CDC data shows Americans died at the lowest rate ever recorded in 2025, pointing to a record life expectancy that isn't official yet. Provisional figures.
The peptide gold rush: The MAHA-fueled peptide boom has swelled into a billion-dollar gray market, and an FDA panel weighs which compounded peptides to allow on July 23-24.
1 in 9 now on GLP-1s: A new Gallup poll put current GLP-1 use at 11% of U.S. adults, triple 2024's rate, as obesity slipped to 36.4% from its 2022 peak.
The Ozempic pantry: Because GLP-1s dull the taste buds, Nestlé is reworking recipes with bolder spice and smaller portions to win back medicated palates.
Longevity goes East: As Asia ages fast and rich, luxury longevity clinics are booming there around traditional medicine and food-as-medicine rather than Western biohacking, with Fortune flagging hype ahead of evidence.
Featured
Older lifters whose muscle looks years younger
Exercise keeps muscle strong, but a new Nature Aging study went molecular, reading the gene activity of muscle in older adults who kept training against those who didn't:
Half of aging, gone: in trained older adults, about 50% of the age-related differences in muscle's energy-making genes were simply absent, leaving profiles that looked like a young adult's.
Where it counts: the biggest gap was in the machinery that powers cells, exactly the part of muscle that fades with age and drains strength and stamina.
The honest catch: it compared fit and unfit people, not the same person before and after training, so it shows a strong link, not proof exercise did all the work.
Still, it's a striking look at how much of "normal" muscle aging may not be baked in at all, but a mirror of how much we keep moving.
The takeaway needs no prescription: staying trained keeps muscle young where it matters, and tracking your own strength and biomarkers tells you it's working.
More this week
A way to soften the aging of ovaries
Ovaries age faster than almost any organ we have, and a new Nature Aging study points to a reason: a protein called IL-11 builds up with age and stiffens the ovarian tissue, choking its function. When researchers blocked IL-11 in aged mice and rats, the tissue softened and fertility and hormone balance improved, hinting that even reproductive aging may be partly reversible.
The caveats are real: this is animal work, with human tissue only along to confirm the pattern, and there's no anti-IL-11 treatment for ovaries you can ask for today. But it reframes the ovary as a tunable organ rather than a clock that only runs down, and it lands in a lane longevity too often skips: women's healthspan. Knowing your own hormone picture is where that starts.
An AI-designed drug reaches its final trial
For years, "AI-designed drug" was mostly a promise. This week it got concrete: Insilico Medicine began a Phase III trial of rentosertib, a lung-fibrosis pill whose target and molecule were both found by AI, making it one of the first end-to-end AI-designed medicines to reach a make-or-break final trial.
The disease here is pulmonary fibrosis, not aging itself, but the reason it matters is the method: the same AI that pinned this drug's aging-linked target can be aimed at the biology of aging next. It's a milestone, not a cure. Phase III is where promising drugs often stumble, and the earlier human data, while encouraging, was small. But the machine that designs medicines just cleared a bar that used to take a decade of human-only work.
On the radar
Mark July 12-15: the Alzheimer's Association International Conference, the world's largest dementia-research meeting, convenes in London and online, where the year's freshest brain-aging science and late-breaking treatment data tend to surface first. If you track cognitive longevity, it's the week to watch.
Go deeper at longevity.io